博雅生物(300294.SZ)控股股東董事長回覆深交所問詢函:其本人不是公司實控人,亦不存在實際控制公司情形
格隆匯9月14日丨博雅生物(300294.SZ)控股股東高特佳集團董事長蔡達建回覆深交所問詢函稱,其本人無意繼續增持高特佳集團股權,亦無意控制湖州凱佳。從博雅生物和高特佳集團的股東構成、背景、董事會及管理層等情況看,蔡達建本人不是博雅生物的實際控制人,亦不存在實際控制博雅生物的情形。
蔡達建表示,高特佳投資集團致力於更廣泛地投資於健康醫療領域更多的優秀公司,而非專注於收購併經營某一家實體企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.